July 15, 2008
Cytheris Wins E1.5 Million OSEO Grant for HCV Program
Cytheris has announced that OSEO, France's national agency for industrial innovation, has awarded the company with a no interest loan of E1.5 million to support its ongoing clinical development program in hepatitis C.
The OSEO award will provide partial funding for the hepatitis C virus (HCV) clinical development program of the company's lead product, recombinant human Interleukin-7 (r-hIL-7), a critical growth factor for immune T-cell recovery and enhancement.
Michel Morre, president and CEO of Cytheris, said: "This new OSEO support provided for our HCV study will partially cover the manufacturing, clinical studies and personnel costs associated with the program as well as its expansion to include additional clinical sites in Asia."